Business Of Biotech cover image

Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD

Business Of Biotech

00:00

The Future of Vincirix

Our VIP 943 is going in the clinic right now. Next year, we're planning our CXER5 antibody drug conjugate. We have a very unique linker and the capability of different types of linkers. So there's more to build into our pipeline that we are currently working on.

Play episode from 39:00
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app